Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SELTS:0IRF -1.57%50 OCF Yield % is -18.86 as of Aug. 18, 2026. GuruFocus rates LTS:0IRF with a GF Score™ of 50/100 and a GF Value™ of €6.11 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Evotec SE ranks worse than 91.04% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Evotec SE OCF Yield % Related Terms
Evotec SE OCF Yield % Historical Data
* Premium members only.
The historical data trend for Evotec SE's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IRF vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Evotec SE's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (LTS:0IRF) has a OCF Yield % of -18.86 as of Aug. 18, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #914 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 91%.
Is Evotec SE's OCF Yield % too high?
Evotec SE's current OCF Yield % is -18.86. Based on the distribution chart, Evotec SE ranks #914 out of 1004 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #914 out of 1004 companies for OCF Yield %. This places Evotec SE in the lower half of its industry. The industry median OCF Yield % is 3.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.38, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current OCF Yield % is -18.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (LTS:0IRF) is currently considered Possible Value Trap. The stock's GF Value™ is €6.11, compared to a current price of €3.39 — trading 44.5% below its estimated fair value. The current OCF Yield % is -18.86. Evotec SE's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Evotec SE (LTS:0IRF), the current OCF Yield % is -18.86 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (LTS:0IRF) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of €3.39 is trading 44.5% below its estimated GF Value™ of €6.11.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for LTS:0IRF:
OCF Yield %: -18.86
GF Value™: €6.11 vs. price of €3.39 (44.5% below fair value)
No single metric tells the full story. See the LTS:0IRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
50GF Score
Get the complete analysis for LTS:0IRF
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IRF has been successfully added to your 
